Aquestive Granted Preliminary Injunction

WARREN, N.J. /PRNewswire/ -- Aquestive Therapeutics ("Aquestive") announces today that the U.S. District Court for the District of New Jersey has granted Aquestive together with Indivior PLC (LON: INDV) and its U.S. subsidiary, Indivior Inc., a preliminary injunction against Dr. Reddy's Laboratories ("DRL"), mandating the restrictions of the previously entered temporary restraining order (TRO) remain in place. The preliminary injunction prevents DRL from using, selling, offering to sell, or importing its generic buprenorphine/naloxone sublingual film until further order of the district court or of the appellate court.  At issue in the underlying preliminary injunction proceedings was, among other things, the infringement of U.S. Patent No. 9,931,305 (known as the "305 patent") by DRL. 

Keith J. Kendall, CEO of Aquestive, said: "This decision once again demonstrates the significant value our intellectual property has created for Aquestive, its products and our partners." He added, "We continue to believe that DRL's challenge to our patents is without merit."

Media inquiries:

Christopher Hippolyte

christopher.hippolyte@syneoshealth.com

212-364-0458

Investor inquiries:

Stephanie Carrington

stephanie.carrington@icrinc.com

646-277-1282